purpos
despit
controversi
role
corticosteroid
cs
frequent
administ
patient
viru
infect
sever
respiratori
failur
secondari
viral
pneumonia
hypothes
invas
pulmonari
aspergillosi
ipa
frequent
complic
critic
ill
patient
viru
infect
cs
may
contribut
complic
method
retrospect
select
adult
patient
confirm
viru
infect
admit
intens
care
unit
icu
two
tertiari
care
hospit
septemb
march
differ
baselin
factor
risk
factor
outcom
paramet
studi
patient
without
ipa
result
critic
ill
patient
confirm
develop
ipa
day
icu
admiss
five
patient
proven
four
probabl
ipa
significantli
ipa
patient
receiv
cs
within
day
icu
admiss
versu
p
ipa
patient
also
receiv
significantli
higher
dose
cs
icu
admiss
hydrocortison
equival
versu
mg
p
multivari
analysi
use
cs
icu
admiss
independ
associ
ipa
odd
ratio
p
conclus
ipa
diagnos
critic
ill
patient
viru
infect
median
day
icu
admiss
data
suggest
use
cs
day
icu
admiss
independ
risk
factor
fungal
superinfect
find
may
consequ
clinic
practic
point
need
increas
awar
ipa
especi
critic
ill
patient
alreadi
receiv
cs
abstract
purpos
despit
controversi
role
corticosteroid
cs
frequent
administ
patient
viru
infect
sever
respiratori
failur
secondari
viral
pneumonia
hypothes
invas
pulmonari
aspergillosi
ipa
frequent
complic
critic
ill
patient
viru
infect
cs
may
contribut
complic
method
retrospect
select
adult
patient
confirm
viru
infect
admit
intens
care
unit
icu
two
tertiari
care
hospit
septemb
march
differ
baselin
factor
risk
factor
outcom
paramet
studi
patient
without
ipa
result
critic
ill
patient
confirm
develop
ipa
day
icu
admiss
five
patient
proven
four
probabl
ipa
significantli
ipa
patient
receiv
cs
within
day
icu
admiss
versu
p
ipa
patient
also
receiv
significantli
higher
dose
cs
icu
admiss
hydrocortison
equival
versu
mg
p
multivari
analysi
use
cs
icu
admiss
independ
associ
ipa
odd
ratio
p
conclus
ipa
diagnos
critic
ill
patient
viru
infect
median
day
icu
admiss
data
suggest
use
cs
day
icu
admiss
independ
risk
factor
fungal
superinfect
find
may
consequ
clinic
practic
point
need
increas
awar
ipa
especi
critic
ill
patient
alreadi
receiv
cs
sinc
june
infect
influenza
viru
reach
pandem
proport
minor
patient
viru
infect
need
hospit
develop
rapidli
progress
pneumonia
ensu
profound
inflammatori
respons
caus
sever
form
acut
lung
injuri
call
acut
respiratori
distress
syndrom
ard
either
isol
part
multipl
organ
dysfunct
syndrom
mod
ard
due
infect
associ
high
mortal
rate
controversi
exist
regard
use
antiinflammatori
agent
corticosteroid
cs
ard
initi
metaanalysi
conclud
definit
role
cs
ard
establish
recent
one
report
improv
mortal
well
length
stay
less
organ
dysfunct
earli
lowto
moderatedos
cs
subgroup
ard
patient
despit
controversi
role
cs
administ
patient
ard
secondari
viru
infect
howev
sever
recent
studi
report
possibl
harm
effect
cs
sever
pneumonia
due
viru
infect
two
group
investig
found
cs
administr
earli
cours
ard
associ
significantli
higher
icu
hospit
mortal
martinloech
et
al
also
report
worldwid
popul
earli
use
cs
result
better
outcom
associ
increas
risk
superinfect
remark
use
cs
associ
increas
incid
invas
aspergillosi
chronic
obstruct
pulmonari
diseas
copd
patient
sever
respiratori
insuffici
invas
aspergillosi
also
describ
dread
complic
high
mortal
critic
ill
patient
without
malign
neutropenia
recent
clinic
report
suggest
cs
therapi
may
associ
increas
icuacquir
pneumonia
possibl
favor
fungal
superinfect
patient
viru
infect
howev
studi
includ
patient
critic
ill
patient
viru
infect
found
develop
invas
pulmonari
aspergillosi
ipa
addit
case
report
ipa
fungal
superinfect
critic
patient
viru
infect
describ
recent
present
observ
studi
hypothes
ipa
much
frequent
complic
critic
ill
patient
use
cs
may
contribut
superinfect
retrospect
review
medic
record
patient
admit
adult
intens
care
unit
two
tertiari
hospit
univers
hospit
leuven
uzl
leuven
belgium
antwerp
univers
hospit
uza
edegem
belgium
septemb
march
viru
infect
diagnos
week
prior
icu
stay
medic
icu
uzl
bed
wherea
mix
icu
uza
bed
patient
year
old
exclud
diagnosi
viru
infect
base
posit
result
probebas
reversetranscriptas
polymeras
chain
reaction
rtpcr
test
nasopharyng
swab
bronchoalveolar
lavag
bal
observ
retrospect
studi
without
specif
intervent
review
approv
hospit
institut
review
board
data
process
anonym
inform
consent
waiv
ethic
committe
remaind
manuscript
abbrevi
patient
viru
infect
patient
sake
simplic
invas
pulmonari
aspergillosi
diagnos
base
revis
eortcmsg
consensu
group
european
organ
research
treatment
cancerinvas
fungal
infect
cooper
group
nation
institut
allergi
infecti
diseas
mycos
studi
group
guidelin
patient
proven
ipa
microscop
evid
dichotom
branch
hypha
posit
cultur
aspergillu
spp
endobronchi
biopsi
bal
irrespect
host
factor
clinic
featur
probabl
ipa
requir
host
factor
clinic
featur
mycolog
evid
aspergillosi
sinc
host
factor
revis
eortc
definit
basic
intend
immunocompromis
hematolog
patient
defin
broader
risk
factor
base
modifi
eortc
criteria
accord
previou
prospect
studi
valu
bal
diagnosi
aspergillu
icu
patient
mycolog
evid
base
microscopi
cultur
aspergillu
spp
cultur
bal
specimen
galactomannan
gm
optic
index
bal
serum
sampl
sandwich
enzymelink
immunosorb
assay
elisa
gm
detect
platelia
aspergillu
biorad
laboratori
marneslacoquett
franc
perform
accord
instruct
manufactur
lower
tract
respiratori
sampl
inocul
onto
sabouraud
agar
day
anoth
day
fungal
isol
aspergillu
speci
identifi
cultur
characterist
morpholog
studi
period
routin
baselin
monitor
perform
icu
highrisk
ward
take
care
oncolog
hematolog
transplant
patient
monitor
perform
least
year
sever
ill
assess
base
acut
physiolog
chronic
evalu
score
apach
ii
score
sequenti
organ
failur
assess
sofa
score
h
admiss
patient
consid
immunosuppress
baselin
case
underli
malign
hematolog
diseas
solidorgan
transplant
recipi
ill
necessit
immunosuppress
therapi
neutropenia
defin
neutrophil
day
center
dose
frequenc
drug
administ
month
admiss
icu
record
medic
record
patient
data
manag
system
pdm
metavis
imdsoft
boston
usa
day
icu
admiss
call
day
cs
dose
express
mg
hydrocortison
equival
outcom
measur
includ
icu
hospit
surviv
length
stay
day
organ
support
mechan
ventil
inhal
nitric
oxid
highfrequ
rescu
ventil
extracorpor
membran
oxygen
ecmo
vasopressor
renal
replac
therapi
icu
complic
bacteremia
ventilatorassoci
pneumonia
center
cs
start
icu
patient
refractori
shock
andor
late
ard
accord
treat
physician
judgement
data
analyz
spss
spss
inc
chicago
usa
data
report
percentag
categor
variabl
mean
standard
deviat
sd
median
interquartil
rang
iqr
appropri
continu
variabl
univari
analysi
categor
variabl
compar
fisher
exact
test
continu
variabl
compar
test
mannwhitney
u
test
appropri
multivari
analysi
done
backward
forward
stepwis
logist
regress
includ
known
risk
factor
ipa
baselin
factor
significantli
differ
ipa
nonipa
patient
test
signific
twotail
p
valu
consid
signific
septemb
march
includ
adult
critic
ill
patient
confirm
infect
uzl
uza
tabl
total
number
admiss
studi
period
eighteen
patient
season
season
infect
diagnos
icu
stay
patient
diagnos
shortli
icu
admiss
patient
patient
mean
age
year
men
admiss
mean
apach
ii
score
median
sofa
score
reflect
high
sever
ill
high
incid
mod
thirtyf
patient
mechan
ventil
median
durat
day
seven
patient
receiv
cs
icu
stay
rescu
therapi
late
ard
twentyon
patient
need
rescu
therapi
ventil
refractori
hypoxemia
patient
receiv
ecmo
baselin
factor
describ
tabl
twentythre
percent
critic
ill
patient
develop
ipa
earli
day
icu
admiss
day
diagnosi
tabl
figur
reflect
distribut
case
icu
time
proport
patient
diagnos
ipa
includ
patient
least
one
lower
tract
respiratori
sampl
inocul
onto
sabouraud
agar
fungal
isol
aspergillu
fumigatu
isol
lower
respiratori
tract
sampl
cultur
case
ipa
one
ipa
patient
microbiolog
data
limit
gm
detect
bal
serum
combin
new
bilater
infiltr
chest
xray
macroscop
white
pseudomembran
lesion
bronchoscopi
unfortun
biopsi
specimen
bronchial
lesion
lost
microscop
microbiolog
process
five
patient
proven
diseas
probabl
infect
diagnos
patient
one
latter
four
patient
posit
aspergillu
bal
cultur
four
patient
posit
bal
gm
tabl
patient
receiv
amoxicillinclavulan
piperacillintazobactam
day
posit
gm
detect
multipl
confirmatori
posit
gm
sampl
clearli
separ
time
day
later
latest
administr
antibiot
n
proven
fungal
infect
n
ipa
patient
receiv
voriconazol
day
time
icu
admiss
work
progress
either
two
hospit
vicin
patient
ward
center
extens
environment
fungal
sampl
perform
regularli
icu
hospit
ward
season
environment
fungal
isol
could
detect
increas
compar
previou
year
four
nine
ipa
patient
transfer
referr
hospit
data
regard
environment
fungal
sampl
referr
hospit
avail
tabl
present
differ
baselin
characterist
risk
factor
outcom
paramet
ipa
nonipa
patient
ipa
patient
mostli
men
patient
known
liver
cirrhosi
neutropenia
icu
stay
differ
number
ipa
versu
nonipa
patient
develop
ventilatorassoci
pneumonia
ipa
patient
bacteremia
icu
admiss
importantli
icu
stay
significantli
ipa
patient
receiv
cs
icu
admiss
nonipa
patient
versu
p
two
ipa
patient
receiv
cs
icu
admiss
receiv
cs
icu
stay
ipa
diagnosi
first
one
day
day
icu
admiss
onward
septic
shock
one
day
onward
late
ard
dosag
cs
intak
also
significantli
higher
ipa
group
cumul
equival
hydrocortison
dose
versu
mg
p
moreov
multivari
analysi
includ
also
sex
known
risk
factor
ipa
use
cs
icu
admiss
independ
associ
presenc
ipa
p
retrospect
studi
show
critic
ill
patient
admit
icu
viral
infect
develop
invas
aspergillosi
earli
day
icu
admiss
day
diagnosi
use
cs
day
icu
admiss
independ
risk
factor
complic
best
knowledg
studi
first
one
report
high
incid
proven
probabl
ipa
critic
ill
patient
five
nine
ipa
patient
proven
ipa
base
microscop
evid
aspergillu
endobronchi
biopsi
four
ipa
patient
diagnos
probabl
ipa
use
modifi
eortc
criteria
icu
patient
publish
previous
increas
evid
inde
show
icu
patient
frequent
develop
ipa
even
without
classic
risk
factor
accord
revis
eortc
criteria
inher
limit
appli
report
incid
invas
aspergillosi
icu
patient
de
pauw
et
al
also
explicitli
acknowledg
limit
paper
revis
eortc
definit
modifi
diagnosi
probabl
ipa
icu
popul
examin
multicentr
studi
final
key
messag
paper
draw
attent
icu
physician
fact
new
risk
categori
develop
ipa
steroid
use
may
identifi
indic
need
high
level
clinic
vigil
detect
extrem
danger
treatabl
coinfect
prospect
studi
martinloech
et
al
report
fungal
superinfect
ipa
cstreat
critic
ill
patient
kim
et
al
found
comparison
two
studi
notic
patient
sicker
receiv
cs
prior
icu
admiss
could
explain
higher
incid
ipa
studi
moreov
diagnost
approach
includ
bal
cultur
also
implement
gm
detect
serum
bal
latter
test
valid
valuabl
diagnost
tool
prospect
studi
icu
extens
environment
fungal
sampl
icu
well
hospit
ward
indic
outbreak
ipa
studi
period
icu
year
flu
season
meersseman
et
al
report
incid
proven
probabl
ipa
icu
unit
uzl
current
studi
perform
retrospect
studi
januari
icu
patient
proven
probabl
ipa
prospect
followup
studi
juli
decemb
author
found
icu
patient
proven
probabl
ipa
besid
high
incid
ipa
line
other
also
found
wors
outcom
ipa
patient
icu
hospit
length
stay
significantli
higher
ipa
patient
sever
reason
critic
ill
patient
pneumonia
due
risk
develop
aspergillosi
first
influenza
virus
report
caus
cellmedi
destruct
airway
epithelium
disrupt
normal
mucociliari
clearanc
foster
colon
invas
aspergillu
spp
sinc
case
aspergillu
superinfect
associ
influenza
report
recent
studi
lung
patholog
fatal
case
suggest
viral
overload
lead
alter
immun
respons
fatal
case
lead
necrot
pneumonia
shown
increas
lactat
dehydrogenas
ldh
level
ideal
breed
medium
fungal
colon
growth
hypha
secondli
cs
frequent
administ
conjunct
antivir
agent
order
limit
inflamm
lung
parenchyma
cs
diminish
host
defens
increasingli
recogn
risk
factor
develop
aspergillosi
icu
patient
cs
exert
immunosuppress
effect
via
transcript
inhibit
nuclear
factorkappab
nfjb
lead
inhibit
cellular
immun
monocyt
tlymphocyt
polymorphonuclear
leukocyt
pmn
essenti
defens
ipa
moreov
vitro
experi
show
enhanc
growth
aspergillu
spp
cs
exposur
final
cs
may
also
hinder
efficaci
antifung
therapi
administr
cs
may
especi
detriment
sever
influenza
pneumonia
possibl
favor
persist
viral
replic
also
suggest
differ
recent
clinic
report
li
et
al
report
cs
administr
result
increas
rate
secondari
infect
sever
acut
respiratori
syndrom
sar
patient
howev
retrospect
design
studi
allow
conclus
causal
relationship
cs
ipa
limit
number
patient
studi
also
limit
robust
multivari
analysi
studi
earli
cs
administr
icu
admiss
appear
relev
sinc
ipa
acquir
earli
icu
admiss
conclus
found
signific
amount
critic
ill
patient
viru
infect
develop
ipa
soon
admiss
icu
use
cs
prior
icu
admiss
appear
one
main
risk
factor
find
may
consequ
daili
clinic
practic
threshold
activ
search
invas
aspergillosi
critic
ill
patient
via
bal
cultur
gm
detect
low
patient
treat
cs
warrant
special
attent
moreov
one
cautiou
give
steroid
mechan
ventil
patient
suffer
conclus
need
confirm
larger
studi
